Anavex Life Sciences Corp. reported fiscal 2026 first quarter results and provided a business update focused on its lead oral blarcamesine program in early Alzheimer’s disease and other central nervous system disorders.
For the quarter ended December 31, 2025, Anavex recorded a net loss of $5.7 million, improved from a net loss of $12.1 million a year earlier. Operating expenses fell to $6.8 million from $13.6 million, reflecting lower general and administrative as well as research and development spending. Net loss per share narrowed to $0.06 from $0.14, on a higher weighted average share count of 89,029,458 basic and diluted shares, up from 84,805,974.
The company ended December 31, 2025 with $131.7 million in cash and cash equivalents, up from $102.6 million as of September 30, 2025, and total stockholders’ equity of $126.6 million, compared with $94.9 million at September 30, 2025. Management reiterated its focus on advancing blarcamesine and other pipeline candidates and hosted a webcast to discuss the quarter.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.